FOTIVDA

This brand name is authorized in Austria, Croatia, Estonia, Finland, Ireland, Lithuania, Netherlands, New Zealand, Poland, Romania, Spain, UK.

Active ingredients

The drug FOTIVDA contains one active pharmaceutical ingredient (API):

1	Tivozanib UNII 172030934T - TIVOZANIB
	Tivozanib potently and selectively blocks all 3 Vascular Endothelial Growth Factor receptors (VEGFR) and has been shown to block various VEGF-induced biochemical and biologic responses in vitro. By blocking VEGF-induced VEGFR activation, tivozanib inhibits angiogenesis and vascular permeability in tumour tissues, leading to inhibition of tumour growth in vivo.
	Read more about Tivozanib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
FOTIVDA Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EK03		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
Discover more medicines within L01EK03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1752544, 1752555
ES	Centro de información online de medicamentos de la AEMPS	1171215001, 1171215002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	077037, 160840
GB	Medicines & Healthcare Products Regulatory Agency	350405, 357358
IE	Health Products Regulatory Authority	88824, 88825
LT	Valstybinė vaistų kontrolės tarnyba	1083794, 1083795
NL	Z-Index G-Standaard, PRK	149497, 149500
NZ	Medicines and Medical Devices Safety Authority	20166, 20190
PL	Rejestru Produktów Leczniczych	100400587, 100400601
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66271001, W66272001